天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook--->CAS DataBase List--->2011-67-8

2011-67-8

2011-67-8 Structure

2011-67-8 Structure
IdentificationMore
[Name]

Nimetazepam
[CAS]

2011-67-8
[Synonyms]

1,3-dihydro-1-methyl-7-nitro-5-phenyl-2h-1,4-benzodiazepin-2-one
1-methyl-7-nitro-5-phenyl-1h-1,4-benzodiazepin-2(3h)-one
NIMETAZEPAM
1,3-dihydro-1-methyl-7-nitro-5-phenyl-2h-4-benzodiazepin-2-one
1-Methyl-5-phenyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
1-Methyl-7-nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
1-Methylnitrazepam
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-1-methyl-7-nitro-5-phenyl-
Elimin
Hypnon
Nimetazam
Nitrazepam, methylated
ro5-3453
S 1530
N-Methylmogadon
[EINECS(EC#)]

217-931-5
[Molecular Formula]

C16H13N3O3
[MDL Number]

MFCD00242916
[Molecular Weight]

295.29
[MOL File]

2011-67-8.mol
Chemical PropertiesBack Directory
[Melting point ]

156.5-157.5°
[Boiling point ]

436.98°C (rough estimate)
[density ]

1.1952 (rough estimate)
[refractive index ]

1.6500 (estimate)
[Fp ]

9℃
[storage temp. ]

-20°C
[solubility ]

Chloroform (Slightly), Methanol (Slightly)
[form ]

Solid
[pka]

pKa 2.53(EtOH/H2O,t =25,Iundefined) (Uncertain)
[color ]

Light Yellow to Dark Yellow
[CAS DataBase Reference]

2011-67-8(CAS DataBase Reference)
[NIST Chemistry Reference]

Nimetazepam(2011-67-8)
Safety DataBack Directory
[Hazard Codes ]

F,T
[Risk Statements ]

11-23/24/25-39/23/24/25
[Safety Statements ]

16-36/37-45
[RIDADR ]

UN1230 - class 3 - PG 2 - Methanol, solution
[WGK Germany ]

1
[Toxicity]

LD50 in male, female mice, rats (mg/kg): 910, 750, 1150, 970 orally; 970, 840, 970, 980 i.p.; 1500, 1500, 1000, 1000 s.c. (Sakai)
[DEA Controlled Substances]

CSCN: 2837
CSA SCH: Schedule IV
NARC: No
Hazard InformationBack Directory
[Chemical Properties]

Dark yellow Solid
[Originator]

Erimin,Sumitomo,Japan,1977
[Uses]

Sedative, hypnotic. Controlled substance.
[Definition]

ChEBI: A nitrazepam which is substituted at positions 1 by a methyl groups. It is used as an anticonvulsant and as a hypnotic for the short-term management of insomnia.
[Manufacturing Process]

To a suspension of 73.9 g of 1-methyl-5-nitro-3-phenylindole-2-carbonitrile in 1.5 liters of dry tetrahydrofuran is added dropwise a solution of 126 g of boron trifluoride etherate in 220 ml of dry tetrahydrofuran with stirring for 2 hours. After addition, stirring is continued for an additional 3 hours. To the reaction mixture is added dropwise 370 ml of water and then 370 ml of concentrated hydrochloric acid with stirring under ice-cooling.
The resulting precipitate is collected by filtration, washed with water followed by ethanol, and dried to give 56.3 g of crude 2-aminomethyl-1-methyl-5- nitro-3-phenylindole hydrochloride, melting point 263°C to 267°C.
To a suspension of 6.5 g of 2-aminomethyl-1-methyl-5-nitro-3-phenylindole in 65 ml of glacial acetic acid is added dropwise a solution of 6.5 g of chromic anhydride in 6.5 ml of water at 20°C with stirring. The mixture is stirred at room temperature overnight and thereto is added 195 ml of water. To the mixture is added dropwise 100 ml of 28% ammonia water with stirring under cooling. The resultant precipitate is collected by filtration, washed with water and dried to give 5.9 g of a crude product having melting point 135°C to 140°C. Fractional recrystallization from ethanol gives 3.8 g of 1-methyl-7- nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one as yellow plates, melting point 153°C to 156°C. Further recrystallization from the same solvent gives pale yellow plates having melting point 156°C to 156.5°C.
[Therapeutic Function]

Tranquilizer
Tags:2011-67-8 Related Product Information
96-33-3 99-76-3 1779-49-3 143390-89-0 6674-22-2 31828-71-4 79-20-9 768-33-2 138-24-9 2011-67-8 74-83-9 146-22-5 298-00-0 1622-61-3

This site uses cookies
This website uses cookies and similar technologies to store and retrieve information about your use of this website. This information helps us to provide, analyse and improve our services, which may include personalised content or advertising. We may share this information with Google and other third parties. This cookies are necessary for our website to work properly . By clicking "Continue" or continuing to browse our site you are agreeing to our and our partners use of cookies.
Accept